Study Shows Gradual Addition Of NovoLog® At Mealtime Can Reduce A1c In Type 2 Diabetes Patients

Links shared publicly online about this topic.

  • 1,059
    total visits

Study Shows Gradual Addition Of NovoLog® At Mealtime Can Reduce A1c In Type 2 Diabetes Patients

medicalnewstoday.com —

Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, pres

View full resource at medicalnewstoday.com

Tags: Diabetes, Insulin, Type 2 Diabetes, Novo Nordisk

  • Share

Most Recently Shared on June 30, 2010 at 4:08 am By:

mnt_diabetes MNT Diabetes News

Study Shows Gradual Addition Of NovoLog® At Mealtime Can Reduce A1c In Type 2 Diabetes Patients http://mnt.to/3Ftx #diabetes

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Pharma News MNT Pharma News

MNT Clinical Trials MNT Clinical Trials

Advertisement